Spunky, good to see you are still around. On the surface the split would make sense, but I remember from my conversation with Przybyl, that he wanted a low share total to lower cost. More shares mean higher annual costs more expenses when issuing prospectuses(proxy) etc... I guess time will tell.
Personally, I have wondered if the reason for the low share total would possibly be:
1) To eventually turn Ani into wealth builder for well healed clients.
or
2)To be bought out at some time on the future. Maybe, as part of Abbvie's larger growth strategy as their generic arm, just as Sandoz is the generic arm for Novartis.
Note: This is pure speculation.